文献速递妇科生殖医学

SMARCA4致病性变异:基于实验室检测队列的妇科癌症病史

SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort.
PubMed 文献 · Gynecol Oncol · 2025-10-13

这项回顾性队列研究分析了单一商业临床实验室2014-2024年多基因panel检测中发现的127例SMARCA4胚系致病/可能致病性变异个体,其中53.5%有癌症史,女性中SCCOHT占17.9%、未特指卵巢癌占7.4%,所有SCCOHT均在40岁前诊断。作者认为数据支持将SMARCA4纳入遗传性早发性卵巢癌的基因检测,并强调需开展前瞻性外显率研究。

要点

  • 127例SMARCA4 gPV个体中53.5%(n=68)有癌症史,女性占74.8%。
  • 有癌症史的女性中SCCOHT占17.9%、未特指卵巢癌占7.4%。
  • 所有SCCOHT病例均在40岁前诊断,≤50岁女性癌症诊断中SCCOHT占29.8%。

核心结论

  • 数据支持将SMARCA4纳入遗传性早发性卵巢癌的基因检测,并列举了SCCOHT的诊断年龄。
  • 强调需要前瞻性外显率研究以改善患者及家属的咨询和管理。

研究设计与样本

  • 回顾性队列研究,分析单一商业临床实验室2014-2024年遗传性癌症多基因panel检测中发现的SMARCA4 gPV个体。
  • 共137例携带SMARCA4 gPV,应用排除标准后127例纳入分析。

主要发现

  • 携带SMARCA4 gPV个体以女性为主(74.8%),53.5%(n=68)有癌症史。
  • 有癌症史的女性中,SCCOHT占17.9%,未特指卵巢癌占7.4%。
  • ≤50岁女性癌症诊断中SCCOHT占29.8%。
  • 所有SCCOHT病例均在40岁前诊断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the cancer histories of individuals with a SMARCA4 germline pathogenic/likely pathogenic variant (gPV) obtained through clinical laboratory-based testing to aid in informing guidance surrounding surveillance and prevention for individuals with gPV. METHODS: This retrospective cohort study analyzed individuals with a SMARCA4 gPV identified by multigene panel testing for hereditary cancer at a single commercial clinical laboratory (2014-2024). Descriptive statistics were used to summarize individuals with a gPV in SMARCA4. Age at diagnosis of small cell carcinoma of the ovary hypercalcemic type (SCCOHT) and of unspecified ovarian cancer among individuals with a SMARCA4 gPV was enumerated using cumulative distribution functions. RESULTS: Among genotyped individuals, 137 had a SMARCA4 gPV. After applying exclusion criteria, 127 individuals were included in the analysis. Individuals with a SMARCA4 gPV were predominately female (74.8 %), and 53.5 % (n = 68) had a history of cancer. Of the females with a cancer history, SCCOHT (17.9 %) and ovarian cancer not otherwise specified (7.4 %) were reported. SCCOHT accounted for 29.8 % of cancer diagnoses among females aged ≤50 years. All SCCOHT cases among individuals with SMARCA4 gPVs were diagnosed by age 40. CONCLUSION: Our data support the inclusion of SMARCA4 in genetic testing for hereditary early-onset ovarian cancer, enumerate the ages of SCCOHT diagnosis, and highlight the need for prospective penetrance studies to improve counseling and management for patients and their families.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Borden BA, Rodriguez-Hernandez A, Trottier M, et al. SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort. Gynecol Oncol. 2025. PMID: 41086671. doi:10.1016/j.ygyno.2025.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。